Longevity biotech startup NewLimit announced a $435 million Series C funding round led by Peter Thiel’s Founders Fund. Existing investors Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners also participated, while new backers Thrive Capital, Greenoaks, and Quiet Capital joined the round. The Wall Street Journal reported the company’s valuation at $3.1 billion, more than triple its valuation a year ago.
NewLimit was co-founded by a familiar name in crypto—Brian Armstrong, founder and CEO of Coinbase. In 2021, Armstrong teamed up with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel to invest $110 million and establish the company in South San Francisco, with the mission of developing drugs that extend healthy human lifespan.
From Yamanaka Factors to Cellular Reprogramming
NewLimit’s research rests on a breakthrough made in 2006 by Japanese scientist Shinya Yamanaka. He demonstrated that activating just a few specific transcription factors could reprogram adult cells into a young, embryonic-stem-cell-like state. These factors, later named “Yamanaka Factors,” earned him the 2012 Nobel Prize in Physiology or Medicine and proved for the first time that cellular age is not irreversible.
NewLimit is advancing along this path. As the company states: “Our drugs activate specific transcription factor genes to reprogram the epigenome to a younger state. Such reversal is possible, but the optimal combination of factors for each cell type remains unknown—discovering these effective gene payloads is the core challenge of our work.”
First Liver Disease Drug to Enter Trials Next Year
In its funding announcement, NewLimit revealed that after making breakthrough discoveries, it is now moving longevity medicine into human clinical trials. The first drug, targeting alcohol-related liver disease, is expected to begin clinical trials next year. Co-founder and CEO Jacob Kimmel explained that liver disease can be seen as an “accelerated aging” process—it mirrors the universal aging trajectory but in a faster, more aggressive form, making it an ideal first target for testing cellular reprogramming therapies.
NewLimit is not alone in this space. In 2022, Sam Altman invested $180 million into Retro Biosciences, which is developing drugs to rejuvenate aging cells and recently disclosed a valuation of $1.8 billion. Also in 2022, Altos Labs launched with $3 billion, reportedly backed by Jeff Bezos, and has since nearly doubled its cumulative funding.
The Billionaires’ Race Against Time
From Peter Thiel to Sam Altman to Jeff Bezos, the longevity field consistently draws the world’s wealthiest tech titans. Thiel has openly expressed his distaste for death, repeatedly arguing that “death is humanity’s greatest enemy, yet we treat it as a natural law.” When wealth and power reach their zenith, time becomes the ultimate adversary—the one luxury that money alone cannot buy. The billions being poured into longevity research are a direct reflection of that logic.
